Evidence map›Paper›PMID 35280781›Full record

ArticleFrontiers in oncology2022

Editorial: Strengths and Challenges of Allo-SCT in the Modern Era.

Michele Malagola, Raffaella Greco, Jacopo Peccatori, Alessandro Isidori, Rizwan Romee, Mohamad Mohty, Fabio Ciceri, Domenico Russo

Open access · goldAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Michele MalagolaUnit of Blood Diseases and Stem Cell Transplantation, ASST-Spedali Civili di Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Raffaella GrecoUnit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Jacopo PeccatoriUnit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Alessandro IsidoriHematology and Stem Cell Transplant Center, AORMN Hospital, Pesaro, Italy.
Rizwan RomeeDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, United States.
Mohamad MohtyDepartment of Hematology and Cellular Therapy, "Saint Antoine Hospital" AP-HP, Paris, France.
Fabio CiceriUnit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Domenico RussoUnit of Blood Diseases and Stem Cell Transplantation, ASST-Spedali Civili di Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Brescia · ITDana-Farber Cancer Institute · USSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

allogeneic SCTCARTcytomegalovirus (CMV)immune reconstitutionrelapse prevention

Identifiers

PMID35280781
PMCPMC8907534
OpenAlexW4213447276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.